Increased frequency of HLA-DRB1*15 in patients with multifocal motor neuropathy

Neurology

Volumn 74, Issue 10, 2010, Pages 828-832

  Sutedja, N A ^a   Otten, H G ^b   Cats, E A ^a   Piepers, S ^a   Veldink, J H ^a   Van Der Pol, W L ^a   Van Den Berg, L H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; ONSET AGE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 77949421386     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d3e2f6     Document Type: Article

References (39)

1. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, et al. Multifocal motor neuropathy. Lancet Neurol 2005;4: 309-319.
2. Katz JS, Wolfe GI, Bryan WW, et al. Electrophysiologic findings in multifocal motor neuropathy. Neurology 1997;48:700-707.
3. Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 2007;69:1680-1687.
4. Delmont E, Azulay JP, Giorgi R, et al. Multifocal motor neuropathy with and without conduction block: a single entity? Neurology 2006;67:592-596.
5. Zhang G, Lopez PH, Li CY, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004;127:1085-1100.
6. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-78.
7. Freddo L, Yu RK, Latov N, et al. Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology 1986;36:454-458.
8. Nobile-Orazio E, Meucci N, Barbieri S, et al. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 1993;43:537-544.
9. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-1262.
10. Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in multifocal motor neuropathy? Neurology 2004;62:666-668.
11. Klein J, Sato A. The HLA system: first of two parts. N Engl J Med 2000;343:702-709.
12. Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol 2007;165:1097-1109.
13. Niks EH, Kuks JB, Roep BO, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006;66:1772-1774.
14. Van Asseldonk JT, Van den Berg LH, Van den Berg-Vos RM, et al. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 2003;126:186-198.
15. Hattori N, Yamamoto M, Yoshihara T, et al. Demyelinat-ing and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain 2003;126:134-151.
16. Kuijf ML, van Doorn PA, Tio-Gillen AP, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 2005;239:37-44.
17. van Es HW, Van den Berg LH, Franssen H, et al. Magnetic resonance imaging of the brachial plexus in patients with mul-tifocal motor neuropathy. Neurology 1997;48:1218-1224.
18. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-252.
19. Merkies IS, Schmitz PI. Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients' own clinical judgement in immune-mediated polyneu-ropathies. J Neurol Neurosurg Psychiatry 2006;77:970-972.
20. Nobile-Orazio E. Multifocal motor neuropathy. J Neuro-immunol 2001;115:4-18.
21. McCombe PA, Csurhes PA, Greer JM. Studies of HLA associations in male and female patients with Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J Neuroimmunol 2006; 180:172-177.
22. Fox EJ. Immunopathology of multiple sclerosis. Neurology 2004;63:S3-S7.
23. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007;68:S13-S21.
24. Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002;59:S7-S12.
25. Toyka KV, Gold R. The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 2003;60:S2-S7.
26. Corse AM, Chaudhry V, Crawford TO, et al. Sensory nerve pathology in multifocal motor neuropathy. Ann Neurol 1996;39:319-325.
27. Kaji R, Oka N, Tsuji T, et al. Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol 1993;33:152-158.
28. De Jager PL, Simon KC, Munger KL, et al. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008;70:1113-1118.
29. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009;65:239-248.
30. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis, part I: the role of infection. Ann Neurol 2007;61:288-299.
31. Terenghi F, Allaria S, Scarlato G, et al. Multifocal motor neuropathy and Campylobacter jejuni reactivity. Neurology 2002;59:282-284.
32. Behan PO. Immune disease and HLA associations with myasthenia gravis. J Neurol Neurosurg Psychiatry 1980; 43:611-621.
33. Pirskanen R. Genetic associations between myasthenia gra-vis and the HL-A system. J Neurol Neurosurg Psychiatry 1976;39:23-33.
34. Compston DA, Vincent A, Newsom-Davis J, et al. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601.
35. De Angelis MV, Notturno F, Caporale CM, et al. Polymorphisms of CD1 genes in chronic dysimmune neuropathies. J Neuroimmunol 2007;186:161-163.
36. Caporale CM, Papola F, Fioroni MA, et al. Susceptibility to Guillain-Barre syndrome is associated to polymorphisms of CD1 genes. J Neuroimmunol 2006;177:112-118.
37. Geleijns K, Schreuder GM, Jacobs BC, et al. HLA class II alleles are not a general susceptibility factor in Guillain-Barre syndrome. Neurology 2005;64:44-49.
38. Badrising UA, Schreuder GM, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004;63: 2396-2398.
39. Wirtz PW, Willcox N, Roep BO, et al. HLA-B8 in patients with the Lambert-Eaton myasthenic syndrome reduces likelihood of associated small cell lung carcinoma. Ann NY Acad Sci 2003;998:200-201.